Since KRAS mutations affect 20–30% of NSCLC patients and their presence is often associated with shorter overall patient survival compared to EGFR mutations, studies suggest that the KRAS mutation is a negative predictor for EGFR-TKI treatments [53,54]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.